The new announcements bring the number of IPOs priced this week to four, coming shortly after South San Francisco ...

Acute pancreatitis is linked to the development of gallstones, which are listed as a side effect with GLP-1 drugs. Ahmed said ...

By rethinking creative as an interactive educational experience, and not just a promotional message, pharmaceutical brands ...

At Lineage Cell Therapeutics, CEO Brian Culley has been working for many years on allogeneic cell therapies across a range of ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price ...

Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, ...

AstraZeneca is already deeply embedded in China's pharma sector, and is hungry for more, pledging $15 billion to an investment programme in the country and signing a mammoth licensing deal with Hong ...

At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap ...

The South San Francisco start-up is offering 17.6 million shares at a price range of $16 to $18, which would give the company ...